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Abstract 
Background: RNA sequencing (RNA‑Seq) in its varied forms has become an indispensable tool for analyzing differential gene 
expression and thus characterization of specific tissues. Aiming to understand the brain barriers genetic signature, RNA seq has 
also been introduced in brain barriers research. This has led to availability of both, bulk and single‑cell RNA‑Seq datasets over 
the last few years. If appropriately performed, the RNA‑Seq studies provide powerful datasets that allow for significant deepen‑
ing of knowledge on the molecular mechanisms that establish the brain barriers. However, RNA‑Seq studies comprise complex 
workflows that require to consider many options and variables before, during and after the proper sequencing process.
Main body: In the current manuscript, we build on the interdisciplinary experience of the European PhD Training 
Network BtRAIN (https ://www.btrai n‑2020.eu/) where bioinformaticians and brain barriers researchers collaborated 
to analyze and establish RNA‑Seq datasets on vertebrate brain barriers. The obstacles BtRAIN has identified in this 
process have been integrated into the present manuscript. It provides guidelines along the entire workflow of brain 
barriers RNA‑Seq studies starting from the overall experimental design to interpretation of results. Focusing on 
the vertebrate endothelial blood–brain barrier (BBB) and epithelial blood‑cerebrospinal‑fluid barrier (BCSFB) of the 
choroid plexus, we provide a step‑by‑step description of the workflow, highlighting the decisions to be made at each 
step of the workflow and explaining the strengths and weaknesses of individual choices made. Finally, we propose 
recommendations for accurate data interpretation and on the information to be included into a publication to ensure 
appropriate accessibility of the data and reproducibility of the observations by the scientific community.
Conclusion: Next generation transcriptomic profiling of the brain barriers provides a novel resource for understand‑
ing the development, function and pathology of these barrier cells, which is essential for understanding CNS homeo‑
stasis and disease. Continuous advancement and sophistication of RNA‑Seq will require interdisciplinary approaches 
between brain barrier researchers and bioinformaticians as successfully performed in BtRAIN. The present guidelines 
are built on the BtRAIN interdisciplinary experience and aim to facilitate collaboration of brain barriers researchers 
with bioinformaticians to advance RNA‑Seq study design in the brain barriers community.
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mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
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Background
Brain barriers: terms and definitions
Central nervous system (CNS) homeostasis is ensured 
by endothelial, epithelial, mesothelial and glial brain bar-
riers that divide the CNS into compartments [1]. CNS 
barriers allow undisturbed neuronal function within the 
parenchyma while ensuring immune surveillance at the 
borders of the CNS.
For the purpose of clarity, we here define some general 
terms, as they lack a cohesive reference within the brain 
barriers community. For the purposes of this manuscript: 
The blood–brain barrier (BBB) is localized at the level 
of endothelial cells of the CNS microvasculature, which 
includes capillaries, pre-capillary arterioles and post-
capillaries venules. BBB characteristics are not intrinsic 
to CNS microvascular endothelial cells but rather rely 
on the continuous crosstalk of cellular and acellular ele-
ments around CNS microvessels, which are referred to as 
the neurovascular unit (NVU). The NVU contains BBB 
endothelial cells, the endothelial basement membrane 
with a high number of embedded pericytes and the glia 
limitans composed of the parenchymal basement mem-
brane and astrocytic endfeet [2]. The blood-cerebrospi-
nal fluid barrier (BCSFB) is composed of epithelial cells 
surrounding the choroid plexuses (ChP), which extend 
into the cerebrospinal fluid (CSF) filled brain ventricles 
(Fig. 1).
The known functions of the BBB and BCSFB include 
inhibition of free diffusion of molecules from the blood to 
the CNS while ensuring rapid efflux of toxic metabolites 
out of the CNS [3]. In addition, both the BBB and BCSFB 
control immune cell entry into the CNS [4–6]. The pre-
sent study does not include references to the following 
CNS barriers: The arachnoid mater, which establishes a 
BCSFB between the dura mater lacking a BBB and the 
CSF filled subarachnoid space [7]. The pia mater, which 
is localized at the surface of the brain and spinal cord and 
embraces the subarachnoid arteries [4]. The glia limitans, 
which ensheaths the entire CNS parenchyma [4].
Endothelial cells of the BBB are biochemically unique
The BBB endothelial cells are characterized by the pres-
ence of molecularly unique, complex and continuous 
tight junctions, in addition to adherens junctions, lack of 
fenestrations and a low rate of pinocytotic activity [8, 9]. 
Moreover, BBB endothelial cells express specific enzymes 
and transporters that allow an efficient transport of 
nutrients into the CNS and efflux of toxic metabolites out 
of the CNS [10, 11]. Despite these unique biochemical 
characteristics, endothelial cells of the BBB share some 
properties with endothelial cells in peripheral micro-
vascular beds. For example, all endothelial cells develop 
adherens junctions and may express tight junction 
proteins, but at the BBB, adherens junctions are accom-
panied by complex and continuous tight junction strands 
surrounding the entire circumference of the brain micro-
vascular endothelial cells [1]. A better understanding of 
the unique structural and functional characteristics of 
the BBB endothelium would significantly improve our 
understanding of the contribution of BBB impairment in 
neurological disorders.
Phenotypic characteristics of the brain barriers are ulti-
mately regulated at the transcriptional level. In fact, the 
analysis of transcription profiles has been a useful tool in 
biomedical research and has had an increasing impact in 
the last few decades. Therefore, different research groups 
have begun to investigate the BBB transcriptome employ-
ing different methodologies. For instance, the first RNA-
Seq study of CNS cells, including the BBB, was published 
10 years ago [12] while a recent study made use of clau-
din-5-GFP reporter mice to sort  GFP+ endothelial cells 
from the brain of mice for subsequent single cell RNAseq 
(scRNA-Seq) [13]. This study identified zonated tran-
scriptional profiles of brain endothelial cells along the 
arteriovenous axis [13]. Other studies have employed 
bulk RNA-Seq of endothelial cells isolated from the brain 
and peripheral tissues of VE-Cadherin-CreERT2-Rosa-
tdTomato mice to isolate endothelial cells from the brain 
and peripheral tissues in health and disease, including 
mouse models of stroke, multiple sclerosis, traumatic 
brain injury and seizures [14]. This molecular profiling 
has defined core BBB genes expressed by brain endothe-
lial cells that become deregulated in pathology, suggest-
ing potential therapeutic targets common to multiple 
neurological disorders [14]. These approaches under-
score the relevance of transcriptomic profiling of the 
brain barrier cells to advance our understanding of the 
molecular pathways underlying brain barriers function 
and dysfunction.
Progression of transcriptional analysis techniques: 
from Sanger to next generation sequencing
Throughout the 1980s, Sanger sequencing was used 
to identify transcripts within tissues and cells, while 
quantitative methodologies, such as quantitative real-
time polymerase chain reaction (qRT-PCR), came 
into prominence in the 1990s. These methods, usu-
ally referred to as low-throughput or ‘first-generation’ 
sequencing, are still being used to this day for specific 
purposes, although they are laborious, costly (for out-
put level) and therefore, not suitable for establish-
ing full transcriptomes of an entire tissue. The new 
millennium brought high-throughput techniques for 
transcriptomics analysis, with microarrays followed 
by next-generation sequencing (NGS) technologies. 
The most relevant in the present context and the most 
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commonly used NGS technique is RNA-Seq, which 
allows advances in the characterization and quantifica-
tion of transcriptomes, including whole transcriptome 
sequencing in a much less laborious and time-consum-
ing fashion compared to previous methods [15–17].
New technologies bring along opportunities that 
allow for a more in depth understanding of known 
mechanisms and the discovery of novel pathways. 
The new challenges and problems must be addressed, 
and so, the field of bioinformatics with its associated 
researchers who are highly specialized data analysts, 
started. In their short history, RNA-Seq methods have 
seen a sharp decline in costs coupled with the improve-
ment of the underlying technology. This translated to 
an exponential increase of studies and groups taking 
advantage of this technology and of the amount of large 
datasets produced and published (Fig. 2).
Transcriptome analysis and brain barriers: challenges 
and manuscript objectives
A major challenge when aiming to compare transcrip-
tome profiles from a given cell is understanding the 
source of the cell and how it was isolated. In the present 
context it is important to highlight that we found discrep-
ancies in the protocols used for isolating brain endothe-
lial cells to be common but remarkably underreported. 
The inaccuracy begins with a lack of consensus in the 
nomenclature for the different CNS vascular segments 
isolated and analyzed, with some laboratories referring to 
brain microvessels when isolating pure capillary fractions 
Fig. 1 The blood–brain barrier in the context of the neurovascular unit and the blood‑CSF barrier. The blood–brain barrier (BBB) is located 
within the neurovascular unit (NVU, left scheme) at the level of the brain parenchymal microvasculature and composed of endothelial cells 
tightly connected by unique tight junctions. It separates brain parenchyma from the peripheral blood. Endothelial cells produce a basement 
membrane in which pericytes are embedded. Astrocyte endfeet closely contact the microvessels and astrocytes lay down the parenchymal basement 
membrane. The choroid plexus (ChP) stroma is separated from the CSF space by the blood‑CSF barrier (BCSFB, right scheme), which is composed 
of ChP epithelial cells tightly connected by apical tight junctions. The apical side of the epithelium faces the CSF, while the basolateral side resting on 
an epithelial basement membrane faces the ChP stroma. The ChP stroma is highly vascularized with blood vessels lacking a BBB and populated by 
immune cells. The endothelial cells produce their own endothelial basement membrane 
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and others referring to capillaries when in fact the iso-
lated microvessels are comprised of a mixture of arteri-
oles, venules and capillaries. Considering the reported 
zonated gene expression of endothelial cells along the 
CNS vascular tree [13], transcriptome profiling studies 
performed on the BBB can hardly be compared, as most 
of the published studies lack an in depth description of 
the CNS endothelial isolation procedures.
To unveil the full power of transcriptome profiling it is, 
thus, essential to have a solid intersection in the fields of 
transcriptome profiling, bioinformatic analysis and clas-
sical brain barriers research. In this manuscript we high-
light the intersection of transcriptomic profiling (with 
an emphasis on RNA-Seq) and the field of studying the 
brain barriers (with an emphasis on the endothelial BBB 
and the epithelial BCSFB). We start by addressing consid-
erations to be taken into account for the overall experi-
mental design, and then elaborate on the multiple and 
essential intermediate steps throughout the workflow, 
including comparing different BBB isolation method-
ologies for RNA-Seq, data analysis and publishing rec-
ommendations. It is not our intention to establish rigid 
rules on how to perform an RNA-seq study in the field of 
brain barriers. Rather, our aim, based on our collabora-
tive approaches in BtRAIN, is to raise awareness of the 
relevance of each experimental step and to highlight the 
relative strengths and weaknesses of the available alter-
natives. We then summarize what we consider essen-
tial information to be included in original manuscripts 
describing RNA-seq to define BBB signature genes in 
health and disease. We are convinced that appropri-
ate availability of information will improve comparabil-
ity and reproducibility of the different studies and thus 
advance quality and cost-efficiency of these studies in the 
field. By setting the stage for datasets that allow for meta-
analysis-based research, our suggestions will furthermore 
allow for the implementation of the 3R rules of experi-
mental animal research by reducing and refining animal 
experimentation.
Main body
Considerations for the experimental design of a BBB 
RNA‑Seq study
Experimental design is possibly the most important 
step of any transcriptomic experiment as the success of 
the project heavily depends on the choices made at this 
early stage. The first step is to have clear and defined 
goals. Questions that should be addressed before start-
ing an experiment include: (i) Is the intent of the experi-
ment to specifically define the transcriptome of the brain 
endothelial cells along the entire vascular tree or rather 
solely of BBB endothelial cells in CNS microvessels or 
even capillaries? (ii) Is the aim to compare the transcrip-
tome of brain endothelial cells at different stages of e.g. 
development or under specific pathological conditions? 
(iii) Is the intent to define the transcriptome of a specific 
tissue (i.e. ChP epithelial cells vs kidney epithelial cells), 
a specific time point (i.e. embryonic vs post-natal BBB 
development) or a specific pathological condition (Mul-
tiple Sclerosis vs Alzheimer’s Disease)? (iv) What are the 
Fig. 2 RNA‑Seq is an increasingly popular tool for transcriptional analysis. Number of searchable publications in Pubmed per year by the terms 
specified in the legend. Data source: Pubmed. Search date 31/12/2019. Y‑axis shows number of publications, X‑axis shows years
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possible batch effects, such as the sacrificing groups of 
experimental animals on different days? These, and other 
similar questions, are known as intrinsic factors and their 
impact on the experimental design is direct, as they are 
defined by the question and objectives of the study.
There are also extrinsic factors that influence experi-
mental design in the form of practical limitations. They 
are (i) biological sample availability, e.g.: human CNS 
tissue is sparse and may not be obtained in the required 
quality to allow for RNAseq analysis. (ii) costs, e.g.: 
pre-sequencing optimization costs as well as sufficient 
sequencing of samples per group to the required depth. 
(iii) time, e.g. time required for breeding experimental 
animals to obtain the required brain barriers genotype, 
time for protocol optimization of the tissue of interest (be 
it BBB, NVU, whole cortex or others) isolation protocol 
and validation of the results and iv) human resources, as 
a transcriptomics project might involve several scientists, 
from the principal investigator to wet lab researchers and 
technicians, sequencing facility technicians and bioinfor-
maticians (Fig. 3).
Guidelines
• Define a clear goal for the transcriptomics study: 
What is the specific intention for the project.
• Consider both extrinsic and intrinsic factors when 
designing an experiment.
• Plan the experiment including the advice from 
the experts involved in the different steps, such as 
sequencing facility staff and bioinformaticians.
Vascular heterogeneity in the CNS to be considered 
when characterizing the BBB transcriptome
The vasculature is heterogeneous throughout the CNS 
[18] (Fig.  4). This heterogeneity is reflected in the tran-
scriptome, and therefore should be considered prior to 
isolating CNS microvessels for a transcriptomic study of 
the BBB. Two main factors are the capillary density and 
the BBB properties, which may in addition be affected by 
age, sex or the pathological conditions investigated.
Capillary density is related to the metabolic demands, 
and thus neuronal activity, of the respective CNS regions 
[19]. The gray matter (GM) of the cerebral cortex harbors 
many neuronal cell bodies and is therefore more meta-
bolically active than the white matter (WM), where the 
myelinated axonal fibers run. Thus, GM harbors a higher 
density of capillaries when compared to WM [20]. In 
addition, there are specific regions in the CNS, such as 
the hippocampus, characterized by a remarkable hetero-
geneity in capillary density [21].
The cellular and molecular characteristics of the 
NVU components are also heterogeneous throughout 
the CNS. Endothelial cells of the BBB present some of 
the highest regional differences. Indeed, expression of 
endothelial junction proteins (occludin, claudin-5 and 
a-catenin) is higher in the WM compared to the GM [22]. 
In the blood spinal cord barrier, the endothelium is less 
tight and is characterized by a lower pericyte coverage 
[18]. Astrocytes also show heterogeneity along the brain 
vasculature, including higher expression of glial fibril-
lary acidic protein (GFAP), an intermediate filament, 
in WM relative to GM [22, 23]. In contrast, the expres-
sion of aquaporin-4 (AQP4), a water channel localized at 
astrocyte endfeet, is more homogenous throughout the 
perivascular glia limitans [22, 24]. Moreover, endothe-
lial cells do not form a BBB throughout the whole CNS. 
Particularly microvessels within the circumventricular 
organs (CVOs) lack BBB properties. CVOs are localized 
around the brain ventricles and fulfill neurosecretory and 
neurosensory functions. The CVOs include the subfor-
nical organ, the vascular organ of the lamina terminalis, 
the area postrema, the median eminence, the neurohypo-
physis, the pineal gland, and also the ChPs (Fig. 4). CVOs 
contain fenestrated microvessels that allow for the free 
diffusion of blood components into the CVO stroma. 
Thus, co-isolation of microvessels from the CVOs should 
be avoided when aiming to specifically analyze the BBB 
transcriptome [25].
The vascular tree presents gradual phenotypic hetero-
geneity, a phenomenon known as zonation, accompanied 
Fig. 3 Workflow for the experimental design of an RNA‑Seq study. 
The research question will guide the initial experimental setup based 
on intrinsic factors. Then, extrinsic limitations should be taken into 
account to adjust and refine the overall design
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by transcriptional differences [13]. Organization of TJs, 
rate of pinocytosis, expression of enzymes such as alka-
line phosphatase,  Na+/K+ ATPase, expression of trans-
porters or efflux pumps or of adhesion molecules are not 
the same in endothelial cells of brain arterioles, capillar-
ies and venules (Table  1) [26], in line with the different 
functions of these vascular segments. In addition, the 
mural cell subsets in these microvascular segments differ, 
with smooth muscle cells embracing arterioles and, to a 
lesser degree, venules, while pericytes are highly concen-
trated at the level of the capillaries [27, 28] (Fig. 5).
Vascular heterogeneity can also be induced by CNS 
pathology, e.g. neuroinflammation, neurodegeneration or 
brain tumors, which may in fact lead to focal alterations 
in the NVU associated with the CNS pathology. This may 
range from changes in cellular composition of the NVU, 
e.g. pericyte drop during stroke, perivascular accumula-
tion of inflammatory cells in multiple sclerosis or to alter-
ations in vessel diameters as observed in brain tumors. 
All these alterations will affect the outcome of estab-
lished brain barrier cell isolation protocols with respect 
to purity of the brain barrier cells as well as RNA stability.
Guidelines
• Consider CNS capillary density of the region of inter-
est to obtain enough RNA yield: capillary density is 
higher in GM compared to WM.
• Consider regional differences in BBB properties. 
Clearly indicate from which CNS region microves-
sels, capillaries or endothelial cells were isolated.
• Consider if you wish to analyze the transcriptome of 
endothelial cells from a specific vascular segment or a 
specific region of the CNS.
• Consider general or regional alterations in BBB prop-
erties when studying CNS pathologies. Clearly indi-
cate from which CNS region and at what disease 
stage the microvessels, capillaries or endothelial cells 
were isolated.
Regional heterogeneity among the four choroid plexus 
to consider for analyzing the BCSFB transcriptome
The choroid plexus (ChPs) protrude into each of the brain 
ventricles, and thus there are two lateral (telencephalic) 
ChPs, one in the third ventricle (diencephalic) and one in 
the fourth ventricle (hindbrain or myelencephalic). There 
is increasing evidence that the gene expression profile of 
each ChP reflects their positional identities. The mouse 
lateral and fourth ventricle whole ChPs present a differ-
ential transcriptome and secretome, as assessed by RNA-
seq and mass spectrometry [41]. A recent single nucleus 
RNA-seq study revealed a unique cellular composition in 
each of the mouse ChPs [42]. Of note, the more regional-
ized cell types were epithelial cells and fibroblasts, while 
ChP endothelial cells were found to be more homogene-
ous across the ventricles.
Although most transcriptomic studies have focused 
on the lateral ChPs, the choice of ChP will influence 
the sequencing results and the comparison with avail-
able datasets. The heterogeneity of the ChP among 
Fig. 4 Regional differences in the brain microvasculature. Schematic representation of a brain sagittal section (left) and a spinal cord transverse 
section (right). Capillary density is higher in the CNS gray matter than in the white matter, according to their differential metabolic activity. The white 
matter of the corpus callosum is highlighted. The microvessels in the circumventricular organs (CVOs, highlighted in blue) lack BBB characteristics, 
rather they are fenestrated and thus permeable to blood components. CVOs include the subfornical organ, the vascular organ of the lamina 
terminalis, the area postrema, the median eminence, the neurohypophysis, the pineal gland, and the choroid plexus
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the four ventricles in the human brain remains to be 
characterized.
Guidelines
• Consider regional transcriptional heterogeneity 
among the four ChPs. The choice of ChP should be 
stated in the methods.
Brief recommendations on how to select a reporter mouse
Many genetically modified mouse models have been 
developed for studying brain barriers development and 
function. For a general overview on the available genetic 
tools that are used to study the BBB function, we recom-
mend the review of Sohet et  al. [43], while for a study 
involving a solid report in the BCSFB we recommend the 
reading of Johnson et al. [44]. In the context of this man-
uscript the brain barriers reporter mouse lines that allow 
to distinguish brain barriers endothelial or epithelial cells 
from other cells of the CNS by means of expression of a 
fluorescent reporter are of specific interest. While many 
of those mouse lines have been developed for imaging 
purposes they also allow for sorting of the cells of interest 
from the CNS based on expression of their fluorescent 
reporter [12, 13, 45]. For the purpose of this manuscript, 
we will simply mention some recommendations and 
possible pitfalls while using genetic mouse models in 
RNA-Seq studies in the brain barriers field.
Before any experimental approach, a deep understand-
ing of the genetic mouse model that is used is needed. 
To this end, online tools such as http://www.infor matic 
s.jax.org/ can be used to have a detailed overview of the 
mouse line of interest. Original literature on how the 
mouse line has been created and the expression pattern 
of the respective reporter needs to be carefully evalu-
ated. This includes consideration of the promoter used 
for driving the expression of the fluorescent reporter 
with respect to cellular specificity or efficiency of expres-
sion, which could depend also on the age or disease state 
investigated. Furthermore, inducible expression systems, 
e.g. based on Cre-recombinase or TET-ON or TET-OFF-
regulation need to be tested for their specificity, leakiness 
and completeness of driving reporter expression [46, 47]. 
Specificity and intensity of the brain barriers reporter 
expression should always be tested in house prior to 
using the respective mouse model for sorting of brain 
barriers cells.
Considerations for protocols on the isolation 
of CNS microvessels, capillaries or single 
endothelial cells
A RNA-Seq study of CNS microvessels, capillaries or sin-
gle BBB endothelial cells necessarily relies on the protocol 
used to isolate the target tissue or cell. Due to the highly 
Table 1 Segmental heterogeneity in  the  brain microvasculature endothelial cells (arterioles, capillaries and  venules). 
Adapted from [29] and [30]
Presence of perivascular cells is indicated by Yes/No. Presence of BBB features is indicated by Yes/No/non determined (n.d.). Relative expression of transporters/
enzymes is indicated by +, ++ or +++ from lowest to highest expression
Arterioles Capillaries References
Cells
 Smooth muscle cells Yes No [13, 30]
 Pericytes Yes/No Yes [13, 31]
 Perivascular macrophages Yes Yes [13, 30]
BBB features
 Tight junctions (TJs) Continuous and elaborate TJs/? Highly expressed TJs [29, 32, 33]
 Permeability for BBB markers ? No [30, 34]
 Astrocytic end‑foot shealth No Yes [29, 30]
Transporters/enzymes/receptors
 P‑glycoprotein ? +++ [35, 36]
 Na+/K+‑ATPase +++ + [29]
 Transferrin receptor (TFRC) – +++ [13, 37]
 Alkaline phosphatase +++ +++ [29]
 Mg2+‑ATPase +++ + [29]
 5′‑nucleotidase +++ + [29]
 γ‑Glutamyl transpeptidase (GGTP) ? +++ [38, 39]
 Bidirectiona/l vesicular horsedish peroxidase transport +++ + [29, 40]
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a
b
Fig. 5 Heterogeneity in microvasculature diameter determines the outcome of filtration steps for BBB enrichment. a The CNS vascular tree from 
arteries to veins. An indicative range of vessel diameter for each vascular section is provided, along with other cell types that may be co‑isolated. 
Arteries and veins have a diameter > 100 μm, arterioles and venules from 100 μm to 50 μm. The brain microvasculature has a diameter smaller 
than 50 μm and consists of pre‑capillary arterioles, capillaries and post‑capillary venules. Capillaries are generally considered those with a 
diameter < 10 μm and often show diameters of about 5 μm. APC: Antigen‑presenting cell. b Enzymatic digestion and mechanical disruption during 
CNS vascular isolation protocols alter the physical properties of the microvasculature fragments, influencing the downstream steps of the isolation 
protocol, particularly size dependent filtration across nylon membranes. Small vascular fragments obtained by mechanical disruption can allow for 
undesired vessels to pass through the filter. Enzymatic digestion leads to swelling of the blood vessels, prohibiting their elution through the filter
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complex structure of the NVU and the aforementioned 
heterogeneity of NVU components throughout the CNS 
vasculature, a detailed description of the protocol used to 
isolate the material for RNA-seq analysis is mandatory. 
Each step of the isolation protocol is critical and has a 
direct impact on the sample purity as well as on the yield 
of the material obtained for sequencing. To date, many 
different protocols for the isolation of endothelial cells 
of the BBB, or CNS microvessels, or brain endothelial 
cells have been published. Most classical isolation pro-
tocols consist of a combination of mechanical disruption 
and enzymatic digestion and a subsequent size selection 
of the isolated vascular segments by filtration through 
nylon membranes with different pore sizes (Fig. 5). Addi-
tional enrichment of the respective vascular segment is 
usually achieved by density gradient separation [48–50]. 
More refined techniques can be incorporated to increase 
purity, such as selection with antibody-coupled mag-
netic beads or FACS, or taking advantage of fluorescent 
reporter mice [51], as discussed above.
BBB microvessel or capillary isolation
Tissue disaggregation: enzymatic digestion 
versus mechanical disruption
The first step for the isolation of CNS microvessels or 
endothelial cells of the BBB is to properly slice or cut 
the tissue into small pieces in order to facilitate enzyme-
based digestion or the following Dounce homogenization 
steps [52]. Typical techniques of brain tissue disaggre-
gation are either enzymatic or mechanical. Enzymatic 
digestion is often performed using a combination of 
enzymes such as collagenase and dispase as well as 
DNAse. Mechanical disruption, on the other hand, is 
usually performed using Dounce homogenizers with dif-
ferent loose pestle sizes depending on the amount of tis-
sue and the selected species [53, 54]. This ensures tissue 
loosening by shear forces without affecting cell viability. 
Mechanical techniques may prove to be more effective 
while at the same time may be too harsh depending on 
certain factors, such as CNS region or age of the indi-
vidual (i.e. aged tissue is more susceptible to damage). 
Therefore, the choice of technique for tissue disaggrega-
tion can influence the rest of the protocol and should be 
described in detail in the methods of the study.
Microvessel hierarchy selection depending on size: 
filtration steps
Filtration of the dissociated tissue or CNS vasculature 
fragments enriches for a specific component from the 
brain homogenate. One of the most common methods 
for the isolation of CNS microvessels or specifically cap-
illaries is performing either single or a series of filtra-
tions through nylon or polyester membranes followed 
by gradient centrifugation steps with Percoll™, Dextran 
or serum albumin, in order to separate microvessel frag-
ments from cellular debris, myelin and other non-desired 
cell types [55–58].
The enrichment of a certain type of CNS microvessel 
(i.e. capillaries) over the others depends on their diam-
eter and can be achieved by using different filter pore 
sizes. Therefore, the combination of larger (~ 100 μm) to 
smaller (~ 20  μm) filter pore sizes, in addition to using 
one or several filters in sequence, can determine the final 
vascular segment that is isolated [59]. Indeed, the choice 
of meshes should take into account the different vessel 
caliber of the CNS vasculature tree (Fig.  5a). Generally 
speaking, arteries have a diameter ≥ 100  μm, arterioles 
and venules between 100 and 50 μm, post-capillary ven-
ules and pre-capillary arterioles between 50 and 10 μm, 
and capillaries are considered to have a diameter ≤ 10 μm 
[60–62]. The diameter of the arteries decreases from 
the surface of the brain towards the deeper regions [63]. 
Moreover, variability in brain artery diameter between 
different mouse strains has been observed [64], under-
scoring the necessity of a detailed description of the 
source of sequencing material. In humans, CNS vessel 
diameters are affected by the health status of the donor 
[65] while in rat age was shown to contribute to reduced 
capillary diameter in the brain stem [66].
Although size selection represents a possible choice for 
defining the CNS microvascular segment that is isolated, 
some technical details have to be kept in mind. Other 
steps of the protocol can highly influence the physi-
cal properties of the isolated microvessels or capillaries 
(Fig. 5b). For instance, mechanical disruption reduces the 
length of the vasculature fragments and therefore might 
impact size selection. Enzymatic digestion causes swell-
ing of the microvasculature fragments, increasing their 
diameter. Due to these technical aspects, the researcher 
should use the size filtration as a guideline, and empiri-
cally determine the exact fraction of the vascular tree 
that has been purified at the end of the isolation proto-
col (visually analyzing the vascular fragment). Alternate 
tools that help achieve this validation include publicly 
available scRNA-Seq datasets of different BBB cell types 
[13]. These datasets collect information about specific 
cell markers that can be used to complement the isola-
tion. However, it should be clear that expression of a few 
chosen markers might not successfully identify specific 
microvascular segments and that gene expression differ-
ences along brain endothelial cells conform to a gradient 
rather than discrete segments.
In sum, size selection is a critical step in the iso-
lation protocol of microvessels, capillaries or indi-
vidual endothelial cells of the BBB, and ambiguity in 
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terminology should be avoided by accompanying qualita-
tive and quantitative information.
Guidelines
• Tissue processing methods can affect size selection. 
Indicate the method used and, if possible, the state of 
the tissue after dissociation.
• Indicate the size-dependent filtration steps, if used, 
including pore size of the filter mesh and the combi-
nation of more than one filter.
• For animal studies, indicate the strain, age and sex of 
the animals used. For reporter mouse studies indicate 
the precise mouse line used as indicated on the MGI 
homepage (http://www.infor matic s.jax.org).
• For human studies, provide age, sex and relevant 
clinical information of the individuals.
Isolation methods of microvessel fragments 
or single endothelial cells from the BBB
Strategies for BBB purity refinement: selection 
with antibody‑coupled magnetic beads
Selection via magnetic beads coated with specific anti-
bodies represents a useful and precise method to iso-
late microvessels or endothelial cells of the BBB. This 
technique can be used for positive selection of the 
material of interest or for negative selection of possible 
contaminants, alone or combined. For example, to purify 
endothelial cells, positive selection can be achieved by 
using beads coated with anti-CD31 and/or VE-cadherin 
antibodies [67, 68]. On the other hand, beads coated 
with antibodies against CD68, PDGFRβ, NG2 or GLAST 
might be used to specifically select macrophages, peri-
cytes and astrocytes respectively [69–73], or to deplete 
these cells in those cases where a pure endothelial frac-
tion is required. Positive and negative selection may 
be combined in order to improve the specificity of the 
technique.
Despite the high selectivity and improved final purity 
that the bead-mediated selection offers by targeting 
specific cell types, some disadvantages need to be con-
sidered. First, the state of the vessel suspension and the 
physical interaction between different BBB components 
is a critical factor. During the isolation protocol, the brain 
vessels are not revealed in a single cell suspension but 
rather as vascular fragments that consist of tightly con-
nected cell types, such as endothelial cells, pericytes and 
astrocyte endfeet [59]. Prior to bead selection, additional 
disaggregation steps, including enzymatic or mechani-
cal disruption, might aid in obtaining a higher fraction of 
single cells versus microvessel fragments by weakening 
the interaction between different cell types, which may 
enhance the disassociation and determine the outcome 
of the isolation [54]. The close interaction between the 
different components of the BBB [74, 75], makes a total 
single cell suspension from CNS microvessels a chal-
lenging task, ultimately limiting the availability of bind-
ing sites for the antibodies and influencing the isolation 
efficiency if not performed properly. An additional aspect 
to consider is that the enzymatic digestion may influence 
the surface expression of receptors which could be inter-
nalized or lost by shedding or affect presence of surface 
epitopes and thus ultimately cell surface expression of 
potential antigens chosen for positive selection. There-
fore, if the digestion and disaggregation processes are not 
fully achieved, this may lead to low yields despite the high 
purity, which must be taken into account when perform-
ing sequencing analysis since it may influence the down-
stream procedure. Also, extended purification protocols 
aiming to reach single brain endothelial cell suspensions 
bear the risk of inducing changes in gene expression 
in the endothelial cells due to loss of the tight junction 
interactions, as cross-talk between mature cell–cell junc-
tions and the nucleus are well established.
Another important factor is that the selection is based 
on generally accepted markers for the cell population of 
interest, with the above-mentioned limitations. In addi-
tion, heterogeneity in marker expression along the brain 
microvasculature might influence targeting efficiency. 
Therefore, it is good practice to refer to the most recent 
studies that better define different cell populations of the 
brain vasculature [13, 76], in order to improve the target-
ing strategy and the selectivity of the technique.
When using magnetic beads in a positive selection it is 
also important to know how, or if, to separate cells from 
the beads afterwards. A step that might become essen-
tial is when the isolated fraction is intended to be used 
in cell culture. According to the first protocols using this 
method of isolation, incubation of the cells in trypsin/
EDTA at 37  °C releases the beads once the selection is 
achieved [77]. Improvements in this technique allow 
for the establishment of procedures which require a less 
aggressive approach or even do not require detachment 
of the beads following isolation [78], since they do not 
affect growth nor survival of isolated cells. Therefore, also 
depending on the brand, some beads have been shown 
to detach spontaneously from the cultured cells after 
several days, whereas other beads might need a DNAse 
treatment to break the DNA chain that attaches the 
microbead to the antibody [52, 70]. In any case, most of 
the currently used magnetic beads are completely suit-
able for subsequent analysis.
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Guidelines
• Clearly indicate the antibody used to coat the beads 
and the rationale behind the choice; refer to recent 
publications (if possible) to define the cell population 
that will ideally be targeted.
• Clearly indicate the amount of material obtained 
after bead selection, including number of isolated 
cells and amount of RNA extracted from them; this is 
useful information for the study itself and for future 
reference.
• Clearly indicate the necessity of separating beads 
from cells or not, if choosing positive selection of the 
target cell.
Specific separation of microvessel cell populations: 
fluorescence‑activated cell sorting (FACS)
FACS is a powerful technique that uses flow cytometry to 
selectively separate cell populations from complex pools 
of different cells. FACS-based selection has been used in 
transcriptome profiling studies of the brain barriers [13, 
14, 79]. Interestingly, these techniques include high puri-
fication of cells expressing fluorescent reporters in trans-
genic mice, however, any cell that expresses the construct 
will be selected, introducing possible contamination in 
the downstream analysis. For example, FACS has been 
successfully used to enrich brain endothelial cells iso-
lated from claudin-5-GFP mice [13] or tamoxifen-treated 
Rosa-tdTomato; VE-Cadherin-CreERT2 mice [14]. Alter-
natively to fluorescent reporter mice, other studies have 
achieved isolation of brain endothelial cells via FACS by 
antibody staining prior to sorting, using fluorochrome-
conjugated antibodies against CD31 [80, 81] or by a com-
bination of antibodies against CD31 and CD13 to isolate 
endothelial cells and pericytes, respectively, from differ-
ent microregions in the mouse brain [82].
In any case, the final sample after FACS consists of a 
highly enriched fraction of the cell type of interest. How-
ever, a high amount of starting material is often necessary 
to obtain a sufficient yield after the sorting, although it 
will also depend on the needs of the downstream appli-
cation and/or analysis [83, 84]. Also, FACS sorting may 
induce an oxidative stress response in the endothelial 
cells that needs to be considered.
As already mentioned in other sections of this paper 
(e.g.: beads selection), obtaining a viable single cell 
suspension is also crucial when isolating cell popula-
tions of the brain barriers prior to FACS. Similar to the 
beads selection, a combination of mechanical and enzy-
matic digestion prior to FACS is often used to improve 
cell–cell dissociation. Indeed, a good single cell suspen-
sion reduces the amount of false positives/negatives 
produced by antibody staining (when not relying on 
reporter mice) or reporter proteins prior to FACS. In 
line with the necessity of a single cell suspension, duplet 
exclusion should be tightly controlled to ensure the best 
purity and reliability of the sorted material, as well as a 
strict gating strategy according to the experimental needs 
[85]. In addition, abundance of the population of inter-
est is also critical, e.g.: if the level of endothelial cells is 
lower than 15% of the total, the sorted cells might not be 
viable. A density gradient enrichment before performing 
FACS could potentially solve this issue [51]. In general, 
FACS poses some technical challenges and a fine balance 
between time needed for the sorting, quality of the start-
ing material and viability of the sorted cells needs to be 
experimentally tested.
Guidelines
• The flow conditions and the instrument used should 
be indicated.
• The precise scatter and fluorescence gating strat-
egy used for the FACS of the target cell should be 
included in the supplement of the research article, as 
well as a detailed description of the isolation protocol 
and potential staining steps performed prior to the 
sorting and their duration.
• Duration of sorting itself and yield of cells received 
should be described.
• Time of RNA extraction following the FACS should 
be clearly stated, as different experimental designs 
implement differences in time points, e.g.: extraction 
of RNA right after FACS of after several hours due to 
travel from the sorting facility back to the laboratory.
Laser capture microdissection (LCM)
Laser capture microdissection (LCM) allows for the dis-
section of CNS microvessels from a CNS tissue section 
with the help of a microscope and a laser. Dissected CNS 
microvascular endothelial cells can be later captured by 
adsorption, ejection, gravity or aspiration. LCM permits 
to take a snapshot of the transcriptomic profile of the 
BBB, in opposition to methodologies that require long 
incubation times.
One of the main limitations of LCM is the low yield of 
this laborious technique, which can be circumvented by 
using kits designed to isolate RNA from small amounts 
of cells [86] or by performing rounds of RNA amplifica-
tion prior to downstream analysis [87]. However, using 
LCM to capture small cells, such as BBB endothelial cells, 
may be challenging, and contamination from astrocytic 
endfeet and/or pericytes is a major concern. In order to 
improve the cellular purity of the preparation, thinner 
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sections can be used, thus decreasing the chances of 
including cells above or below the plane of interest. Alter-
natively, LCM on cross sections of vessels also provides 
better purity than longitudinal sections, although lower 
yield [88]. To aid the visualization of endothelial cells, 
rapid immunohistochemistry may be coupled to LCM 
[89], in a technique known as immuno-LCM. The repro-
ducibility of immuno-LCM to study BBB gene expression 
in mice has been demonstrated [90]. This technique was 
further validated in human postmortem frozen [87] and 
Formalin-Fixed Paraffin-Embedded (FFPE) brain sections 
[89].
Guidelines
• Consider the balance between yield and purity of the 
isolated CNS microvascular endothelial cells when 
deciding to use cross sections or longitudinal sec-
tions.
• It is recommended to use RNA isolation kits specifi-
cally designed for small amounts of cells, or perform-
ing RNA amplification prior to sequencing.
• Test for and consider the possible cellular contami-
nants co-isolated with the BBB endothelial cells.
BBB in vitro models: cultured primary brain endothelial 
cells and brain endothelial cell lines
Isolated brain microvascular fragments or single cells 
can be cultured and used as a BBB endothelium in vitro 
model. Most of the in vivo BBB characteristics are main-
tained by primary cultures of brain endothelial cells, 
hence representing powerful tools to study various 
aspects of BBB properties. However, often these cul-
tures offer restricted capacity of genetic manipulation 
(e.g. transfection) and can be maintained in culture for 
a limited amount of time and/or passages. Nevertheless, 
numerous primary cultures of brain endothelial cells 
have been established from both mouse [58], rat [91] and 
human [92, 93] brain.
On the other hand, BBB in vitro model established by 
immortalized cell lines allow for much easier handling, 
as in many cases the cells can be cultured and passed as 
needed, in addition to much better tolerance to genetic 
manipulations. This makes cell lines a very suitable tool 
for high-throughput screening purposes, as they are also 
a much more homogenous cell population compared 
to primary cell cultures, where often contaminants are 
found in the culture. As a major drawback, cell lines of 
the BBB endothelium do not strictly retain BBB charac-
teristics such as high tightness and very low permeabil-
ity to the same degree as primary brain endothelial cells, 
therefore careful selection of the best suited BBB cell line 
is needed according to the specific scientific question 
being answered.
In both cases, the presence of additional BBB cell types 
found in vivo is not always modeled in the in vitro sys-
tems, such as for example the presence and anatomical 
disposition of the astrocytic endfeet found in the NVU 
in vivo. To overcome these limitations, sophisticated co- 
or tri-cultures of brain endothelial cells together with 
pericytes or astrocytes from different sources have been 
established and, to a certain degree, mimic the in  vivo 
NVU structure [94–96].
In the context of transcriptomic studies, both BBB cell 
lines and primary brain endothelial cells cultures have 
been successfully used in transcriptomic approaches. 
For example bulk RNA-seq has been performed on the 
human cerebrovascular endothelial cells (hCMEC/D3) 
[97] and on primary mouse brain microvascular endothe-
lial cells (pMBMECs) [79]. Interestingly, a comparative 
microarray analysis between freshly isolated or cultured 
pMBMECs with the endothelioma cell line bEnd.5 has 
highlighted important changes in the mRNA levels of 
genes associated with BBB characteristics [69].
Recent advancements in stem cell technology have 
furthermore allowed derivation of human in vitro mod-
els of the BBB from stem cell sources including human 
cord blood-derived stem cells of circulating endothelial 
progenitors [98] and human induced pluripotent stem 
cells (hiPSCs; summarized in [99]). hiPSCs derived from 
one individual opens the entirely novel opportunity to 
study BBB dysfunction from individual patients as their 
hiPSCs provide a scalable and renewable source for 
establishing brain microvascular endothelial cells. The 
presently available hiPSC derived in  vitro BBB models 
are very well characterized with respect to their barrier 
properties and expression of BBB specific transporters 
and efflux pumps [100–102]. At the same time RNA-Seq 
analysis has shown that hiPSC derived brain microvascu-
lar endothelial cells, as most hiPSCE—derived cells, do 
not fully recapitulate all aspects of the BBB [98]. Present 
hiPSC derived in vitro BBB models, e.g. still lack expres-
sion of the full array of trafficking molecules required for 
immune cell interaction with the BBB.
Guidelines
• Consider the effect of culture-induced mRNA 
expression changes in the in vitro BBB models due to 
medium composition.
• Use RNA-Seq profiling of in  vitro BBB models and 
especially of hiPSC- derived in vitro BBB models to 
benchmark them against the BBB in vivo.
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Considerations for isolating the entire choroid plexus vs 
choroid plexus epithelium
The ChP consists of a highly vascularized stroma popu-
lated by immune cells and is surrounded by a layer of 
highly specialized epithelial cells which form the BCSFB. 
Contrary to the BBB, the ChP endothelium is fenestrated 
and does not form a BBB [103].
ChP transcriptomic studies of the entire ChP tissue will 
include the transcriptome of the epithelial cells forming 
the BCSFB but also from the endothelial cells, stromal 
fibroblasts and immune cells of the ChP. Alternatively, 
the ChP epithelial cells can be isolated to focus on the 
transcriptome of the BCSFB.
Using the whole ChP greatly simplifies the protocol 
for tissue isolation, but the cellular heterogeneity within 
the ChP will complicate subsequent analysis and inter-
pretation of the results especially when performing bulk 
RNAseq studies. However, these studies will provide 
additional information on the other components of the 
ChP, such as the vasculature or immune populations. 
Many RNA-seq studies have taken this approach, par-
ticularly those focused on humans [104, 105].
Alternatively, if the barrier component of the ChP 
is the focus of the study, the epithelial cells can be iso-
lated. While this results in cleaner data, dissociating the 
ChP may be challenging (see below). To overcome these 
difficulties, the novel single-nucleus RNAseq method 
emerges as an option for tissues that are hard to dissoci-
ate, such as the ChP [42].
The research question and the technical limitations will 
determine whether the whole ChP or the isolated epithe-
lium will be sequenced.
Methods for isolating the choroid plexus epithelium
The techniques for isolating the ChP epithelial cells are 
similar to those for the BBB. Of note, the ChP epithelium 
is composed of large cuboidal cells, which are easier to 
dissect microscopically with LCM compared to the thin 
BBB endothelium. Indeed, LCM has been used to isolate 
the human ChP epithelium for microarray studies of the 
BCSFB [106–108]. In animal models, mechanical disrup-
tion of the entire ChP surgically removed from the brain 
ventricles is typically combined with enzymatic digestion. 
In order to release epithelial adherens and tight junctions 
as well integrin mediated adhesive contacts to the epi-
thelial basement membrane, calcium removal is recom-
mended, for example by using the chelator EDTA [109, 
110] or calcium free medium [111], but is not an essential 
requirement [112]. Further purification can be achieved 
by FACS using an epithelial marker such as TTR [41]. 
However, expression of TTR has been recently identi-
fied in ChP macrophages [113], and the choice of mark-
ers should be done with awareness of their limitations. To 
our knowledge, the only human primary epithelial cells 
are those commercially available (ScienCell), and no iso-
lation protocol has been published to date.
Guidelines
• The research question and the technical limitations 
will determine whether the whole ChP or the iso-
lated epithelial cells will be sequenced. This should be 
specified in the methods.
• The ChP can be particularly challenging to dissoci-
ate. The techniques for isolating the ChP epithelium 
include LCM, mechanical and enzymatic digestion. 
Resulting purity should be assessed and reported.
Pre‑sequencing tissue or cell purity assessment
Before performing RNA-seq, it is good practice to ensure 
that the chosen isolation strategy results in the desired 
brain barrier cell purity. Indeed, knowledge about the 
degree of brain barrier cell purity is essential as it dra-
matically reduces possible biases in the downstream 
analysis, overall improving the biological meaningful-
ness of any RNA-seq study. Pre-sequencing purity assess-
ments can be achieved by different techniques, often 
used in combination. Common contaminants when iso-
lating endothelial cells of the BBB are pericytes or peri-
cyte fragments and astrocytic endfeet, which can hardly 
be avoided (Fig. 5, Table 1). These contain RNA and are 
thus readily detectable by assessing expression by qPCR 
of specific markers such as platelet-derived growth factor 
receptor beta (PDGFR-β) or GFAP, respectively. Immu-
nostaining provides information about the location of the 
probed proteins while flow cytometry allows for quanti-
tative detection of the contaminants with higher sensitiv-
ity, although it requires a significantly higher number of 
cells compared to immunofluorescence imaging. There-
fore, qPCR can be used in combination with immunoflu-
orescence imaging in order to estimate the purity at both 
the RNA and protein level. All of the techniques depend, 
to differing degrees, on described cell markers (Table 2).
Another potential source of contaminants when iso-
lating endothelial cells of the BBB are ChP cells, in par-
ticular the ChP epithelium. Indeed, in the vast majority 
of the preparation the ChP is not removed from the 
processed material, therefore potentially accounting for 
contamination. Performing qPCR for choroid plexus 
specific markers such as transthyretin or keratin-8 will 
allow to determine the presence of ChP mRNA in the 
brain endothelial preparation. For example, low expres-
sion of claudin-3 mRNA has been reported in freshly 
isolated brain microvessels, despite recent evidence 
proving lack of claudin-3 expression in the mouse brain 
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microvasculature. This could be due to contamination of 
the isolated brain microvessels with ChP epithelial cells, 
which express claudin-3 [79].
Isolation and purification of RNA from BBB endothelial 
cells or microvessels
RNA isolation methods have to be chosen depending on 
the type and availability of starting material, on the one 
Table 2 Selected molecular markers of relevant CNS cell types with species and methodological information
Italic represents evidence in the mouse, bold italic represents evidence in humans, underline represents evidence in the mouse and humans
IHC immunohistochemistry, RM reporter mice, IF immunofluorescence, PCR polymerase-chain reaction, QPCR quantitative polymerase-chain reaction, RNASeq 
next generation RNA sequencing, scRNAseq single-cell RNA sequencing, KO knock-out, WB Western-blot, ICC immunocytochemical staining, ELISA enzyme-linked 
immunosorbent assay
a A study showing contrary evidence (absence)
Endothelial 
cells 
of the BBB
Pericytes Astrocytes Smooth 
muscle cells
CP/CVO 
endothelial 
cells
CP 
epithelial 
cells
Immune 
cells
Oligodendrocytes Fibroblasts
AQ1 – – – – – [114] IHC
[115] IHC
– – –
AQP4 – – [116] IHC – – [114] IHC – – –
⍺‑SMA – ± IHC [117]
IHC [118]
– [119] IHC – – – – –
CD31/
PECAM1
[120, 121] 
IHC
– – – [122] IHC – [123] IHC – –
Cdh5 [124] – – – [125] RM – – – –
Cldn‑1 [126] IHC – – – – [127–129] 
IHC
– – –
Cldn‑2 – – – – – [127, 128] 
IHC
– – –
Cldn‑3 [130] IF
[79]a
– – – – – – – –
Cldn‑5 [131] 
KO + IHC/
WB
[132] IHC
– – – – [127] IHC – – –
Cldn‑11 – – – – – [128] IHC – IHC [133]
IHC [134]
–
FGF WB [135]
GFAP – – [136] IF – – – – – –
GLAST – – WB [137] – – – – – –
ICAM‑1 [138] IHC
[139] ELISA
[140] ICC – – – – [141] – –
MHC‑II – – – – – – [142] PCR – –
NG2/CSPG4 – [143] IHC – – – – [144] Immunogold –
OAP‑1 – – – – – – – [134] WB + IHC –
Occludin [132] IHC – – – [127] IHC [127, 128] 
IHC
– – –
PDGFR‑β – [143] IHC – – – – – – –
Podoplanin – – – – – [145] IHC, 
WB
[146] IHC
– – –
TTR – – – – – [41] QPCR, 
RNAseq
– – –
VCAM‑1 [147] ELISA [140] ICC – – – – – – –
ZO‑1 [148] IHC
[149] ICC
– – – – [128] IHC – – –
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hand, and the intended RNA-seq analyses, on the other 
(Fig.  6). The use of inappropriate RNA isolation meth-
ods can result in low quantity and/or quality of RNA and 
consequently in less accurate and irreproducible results 
or even in complete failure of the analysis [150].
Contaminations with extrinsic RNA and DNA, or with 
nucleases that might lead to the degradation of RNA 
samples can have a negative impact on the results. Gen-
eral measures to avoid these issues include thorough 
and regular cleaning of work areas and equipment with 
decontamination solution as well as use of clean gloves, 
aerosol barrier pipette tips, and DNAse and RNAse-free 
plasticware. Additionally, it is recommended to carefully 
handle RNA samples at the temperature suggested by the 
manufacturer of the isolation kit [151].
Commercially available RNA isolation protocols gener-
ally follow two main steps: (i) sample lysis, homogeniza-
tion and clearing, and (ii) RNA purification. Isolation kits 
and protocols must be chosen according to the type of 
sample (e.g. cell culture, frozen tissue, FFPE tissue, etc.) 
and RNA molecules to be purified (e.g. small or large 
RNA molecules).
Sample lysis, homogenization and clearing
Cell lysis is commonly performed using a guanidine-thi-
ocyanate-based buffer combined with a strong reducing 
agent, such as tris(2-carboxyethyl)phosphine hydrochlo-
ride, 2-mercaptoethanol or dithiothreitol to ensure the 
complete cell lysis and protein denaturation (lysis buffer), 
but these procedures vary according to the character-
istics of the starting sample (e.g. adherent cell culture, 
cell suspension, frozen tissue or formalin-fixed paraffin-
embedded (FFPE) tissue)—(Fig. 7).
Cultured adherent cells
Cultured adherent cells, like endothelial cells, can be 
subjected to trypsinization prior to cell lysis or they can 
be lysed directly in the culture container by replacing 
the liquid medium with lysis buffer directly to the cell 
monolayer. Cell lysis by addition of lysis buffer is recom-
mended to be performed prior to storage to avoid tran-
scriptomic alterations during freezing. The cell lysate is 
safe to be stored at − 80 °C.
Cell suspensions
Cell suspensions, such as microvessel fragments or single 
endothelial cells, can be pelleted by gentle centrifugation 
(≤ 500×g). After complete removal of the supernatant, 
the cell pellet is re-suspended in lysis buffer. As for the 
lysis of adherent cells, cell lysis is recommended to be 
performed prior to storage. Sorted and isolated single 
cells can be directly collected in lysis buffer and mild lysis 
buffer, respectively.
Tissue samples
At the moment of collection, tissue samples, like the ChP, 
are recommended to be stored in a RNA stabilization 
solution or to be snap-frozen in liquid nitrogen. Sam-
ples in stabilization solution can be stored up to 4 weeks 
at 4  °C or at − 20  °C for long-term storage [152]. Sam-
ples snap-frozen in liquid nitrogen are safe to be stored 
at − 80  °C for more than 20 years [153]. Tissue samples 
might need to be disrupted using different techniques, 
such as the TissueRuptor, TissueLyser, ZR BashingBead 
Lysis Tubes or thorough grinding under liquid nitrogen 
using a mortar and pestle [152]. Remaining tissue and 
other precipitates might need to be removed by centrifu-
gation and the supernatant can be used for subsequent 
RNA isolation.
FFPE tissue samples
FFPE tissue samples derived from brain microvessels 
must be subjected to deparaffinization using xylene or 
other commercially available solutions. Subsequently, 
tissue and protein digestion is performed using protein-
ase K. Next, formaldehyde-derived crosslinks of nucleic 
acids and proteins must be reversed by incubating at 
more than 80 °C. Finally, the sample might be cleared by 
centrifugation and the supernatant can be used for sub-
sequent RNA isolation [154].
RNA purification
During experimental design and before performing RNA 
purification, it is necessary to identify which RNA mol-
ecules are relevant for the research question. Messenger 
Fig. 6 Overview of the main steps for processing a CNS tissue sample into BBB‑related material ready for RNA isolation. Fresh samples are 
dissociated by mechanical disruption, enzymatic digestion, or a combination of both. Typically, tissue is first mechanically disaggregated into 
smaller pieces to facilitate the exposure to the enzyme solution. Dissociated tissue is then selected according to size by passing through one or a 
series of filters, by a density gradient, or both. This process isolates the microvessels. For isolating single barrier cells, tissue dissociation (particularly 
enzymatic digestion) can be repeated [1] after the initial size selection steps. The single cell suspension can be further purified or enriched for 
certain cell types [2] by using a fluorescence‑activated cell sorter (FACS) or magnetic microbeads labeled with an antibody against a cell marker. 
Alternatively, if the tissue of interest is frozen or formalin‑fixed paraffin‑embedded (FFPE), a common approach is to isolate the microvessels by laser 
capture microdissection (LCM)
(See figure on next page.)
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RNA (mRNA) is the RNA that will be translated by 
the ribosomes into proteins. mRNA is characterized 
by having a coding sequence surrounded by 3′ and 5′ 
untranslated regions and a long sequence of adenine 
nucleotides at the 3′ end (poly-A tail). Several other types 
of non-coding RNA have important roles in cell biology, 
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e.g. ribosomal RNA (rRNA) and transfer RNA (tRNA) are 
necessary for the translation process. Additionally, other 
RNA families are important for gene expression regula-
tion as for example, microRNA (miRNA) with a size of 
ca. 22 nucleotides, other small RNAs (< 200 nt) and long 
non-coding RNA (lncRNA) with sizes greater than 200 
nucleotides. Regarding the RNA content in a cell, it is 
important to notice that just mRNA and many lncRNA 
have a poly-A tail at the 3′ end. Additionally, rRNA repre-
sents the majority of the RNA content in the cell.
The combination of a highly concentrated chaotropic 
salt (e.g. guanidinium thiocyanate) in the lysis buffer with 
a certain concentration of an organic solvent (typically 
ethanol or isopropanol) allows the adsorption of nucleic 
acids to the silica matrix in spin columns. Although 
this solid phase extraction allows for efficient and easy 
isolation of purified nucleic acids, several details must 
be taken into consideration. The final concentration of 
ethanol or isopropanol in the mixture with lysis buffer is 
essential to promote the adsorption of RNA to the silica 
matrix [150]. Different ethanol or isopropanol concentra-
tions result in the isolation of RNA molecules with differ-
ent sizes, e.g. small RNA molecules (containing miRNAs) 
with a size between 16 and 200 nucleotides and large 
RNA molecules (containing mRNA and lncRNA) with 
a size greater than 200 nucleotides. Therefore, it is nec-
essary to carefully select the applied protocols and cor-
respondent ethanol/isopropanol concentrations before 
starting the isolation. Due to the possible impact of 
genomic DNA (gDNA) contamination in RNA-seq analy-
ses, thorough digestion of gDNA remnants in RNA sam-
ples is mandatory. gDNA removal columns or integrated 
on-column DNA digestions are included in most RNA 
isolation kits [152].
Guidelines
• The RNA extraction protocol should be selected 
based on tissue type and quantity, as well as the 
intended sequencing and analysis.
• Specific protocols are required for the isolation of 
total RNA including miRNA.
• Correct sample homogenization and clearing are 
essential for isolation efficiency of RNA and analysis 
reproducibility.
Fig. 7 Overview of commonly used RNA isolation protocols. Preparation of BBB‑derived samples according to the type of sample. Cells in 
suspension are first collected by centrifugation, while adherent cultured cells are commonly trypsinized; then lysis buffer is added and cells 
are homogenized before proceeding to isolation of the RNA. Fresh frozen tissue can be mechanically disrupted in lysis buffer; debris should be 
removed by centrifugation before RNA isolation. Formalin‑fixed paraffin‑embedded (FFPE) tissue is first deparaffinized, and tissue disruption can be 
achieved by enzymatic (proteinase K) and/or mechanical means; de‑crosslinking is followed by addition of lysis buffer, and then RNA is isolated
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• Genomic DNA contamination can have a consid-
erable impact on the sequencing results therefore, 
gDNA removal or digestion is mandatory.
RNA quantification and quality control
RNA concentrations are best determined using a fluoro-
metric quantification or qPCR. For example, fluorometric 
quantification can reliably measure RNA concentrations 
as low as 0.2  ng/μl. Spectrophotometric quantification 
is not recommended due to its inaccuracy, especially for 
small amounts of RNA, and due to the unreliable results 
in the presence of contaminants with an absorption 
wavelength close to those of DNA and RNA, e.g. phenol. 
Nonetheless, the spectrophotometer can be a useful tool 
to determine contaminations. For example, measure-
ments with absorption wavelengths of 230 and 280  nm 
can indicate contaminations with guanidinium salts and 
proteins, respectively.
Quality control is best performed using an automated 
capillary electrophoresis platform that calculates a score 
for the RNA quality. Depending on the automated capil-
lary electrophoresis platform used for RNA characteriza-
tion, the RNA quality score might have different names 
(e.g., RNA integrity number, RNA Quality Score, RNA 
Quality Number, etc.). The RNA quality score has values 
between 0 (poor quality) and 10 (good quality) and it is 
calculated using an algorithm that incorporates several 
features of the RNA electropherogram, such as the ratio 
of 28S:18S ribosomal RNA [155]. A quality score for total 
RNA higher than 8 is recommended for the majority of 
RNA-seq library preparation techniques. In case of FFPE 
tissue, samples with score values around 2 can be used 
to perform RNA-seq using specific protocols for library 
preparation [156, 157]. RNA quality scores of the respec-
tive RNA isolates are often missing in RNA-seq datasets 
in public databases, such as Gene Expression Omnibus 
(GEO—https ://www.ncbi.nlm.nih.gov/geo/) or Sequence 
Read Archive (SRA—https ://www.ncbi.nlm.nih.gov/sra). 
Given their impact in study reproducibility and cross-
study meta-analyses it is advisable to include these in 
publications as well as public databases.
Human BBB and BCSFB samples from a clinical setting 
often present suboptimal preservation, which may affect 
the resemblance of the transcriptome to the in vivo situ-
ation. With some exceptions [158–163], the use of biop-
sies from human brains for RNA-seq is uncommon and 
postmortem material is used instead. Two main factors 
should be considered when using postmortem brain or 
spinal cord samples, namely the premortem agonal state 
of the patient and the postmortem delay until sample 
collection. Prior to death, the patient may have suffered 
from fever, sepsis or hypoxic changes, as well as the pro-
vision of oxygen, which will strongly and selectively affect 
the levels of certain mRNAs [164]. Postmortem delay of 
tissue retrieval and preparation hampers RNA integrity 
as a result of transcript degradation, possibly in a non-
random way [165]. RNA integrity can strongly affect 
transcript levels [165]. Particularly, low RNA integrity 
samples present an upregulation in translation‐related 
pathways [166]. The time to sample preservation should 
be minimized, but this is usually not in the hands of 
the researchers. Samples with low RNA quality can be 
excluded by using a certain threshold (as measured by 
the RNA Integrity Number or RIN), or a mathematical 
model can be applied that accounts for the differential 
decay of different transcripts, thus increasing the statisti-
cal power [165].
Other factors that may lead to RNA degradation are 
the handling and storage conditions and, if applicable, 
the sectioning process. However, there are reports of a 
remarkable RNA stability in postmortem human brain 
samples [167, 168].
In summary we advise the starting material to fulfill 
three criteria:
• The RNA quality should be accessed, and the library 
preparation protocol should be chosen accordingly.
• The quantity of isolated RNA must be sufficient to 
perform library preparation. Commercially avail-
able kits allow for preparation of libraries with 0.1 to 
500 ng of total RNA.
• The RNA samples must be clear of contaminants 
such as proteins, salts, sugars or DNA.
Guidelines
• Integrity values for RNA are essential both for the 
selection of the enrichment method as well as sample 
selection.
• Assess RNA quantity and quality of the samples prior 
to sequencing. A quality threshold should be debated 
between the wet-lab researcher, the sequencing tech-
nician and the bioinformatician.
• If the data is made publicly available, always disclose 
the integrity values of the included samples.
• Consider the integrity of the samples when choosing 
the library preparation method (discussed below).
• Consider pre- and postmortem factors: they may 
affect heterogeneity in the whole transcriptome.
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Design and preparation of sequencing libraries
When designing an RNA-Seq experiment, the following 
aspects must be considered: sequencing strategy, library 
preparation, number of replicates and sequencing depth 
(Fig. 3).
The sequencing strategy is important to guarantee 
the quality of the analysis at a reasonable cost. Paired-
end sequencing means sequencing from both ends of 
the cDNA fragment. Since both fragments are aligned 
as a pair of reads, this strategy is preferable for de novo 
transcriptomic assembly, to study isoform expression or 
poorly annotated transcriptomes. Single-end sequenc-
ing implies that just one end of the cDNA fragments is 
sequenced. This approach is more cost-effective than 
paired-end sequencing and it is suitable for studying 
gene expression in well annotated organisms, such as 
human, mouse, rat and zebrafish. Additionally, the length 
of the reads produced during sequencing can be chosen 
depending on the purpose of the study. Longer reads 
(from 150 to 300 bases) are more cost-intensive but offer 
a higher resolution to study alternatively spliced RNA 
isoforms or poorly annotated transcriptomes. Shorter 
reads (e.g. 75 base pairs) are suitable to study gene 
expression in well annotated organisms.
The sequencing depth (number of sequenced reads 
per sample) used in RNA sequencing experiments 
is important for detection of differentially expressed 
genes, especially for lowly abundant transcripts. RNA-
Seq experiments are recommended to use a minimum 
sequencing depth between 10 and 30 million reads per 
sample [169, 170]. However, in human samples, it was 
shown that increasing sequencing depth above the ten 
million reads per sample threshold does not improve the 
identification of differentially expressed genes as much as 
increasing the number of replicates [171].
Inclusion of replicates in RNA-seq experiments is 
important to assess technical and biological variations:
• Technical variability in sequencing is usually low. 
Nonetheless, the technical variability introduced dur-
ing sample collection and library preparation can be 
estimated using technical replicates or RNA spike-in 
like the one developed by the external RNA controls 
consortium (ERCC) [172] The ERCC RNA spike-in is 
a mixture of 92 synthetic RNA molecules and each 
molecule has a defined concentration. This mixture 
can be used to technically validate sequencing results 
and estimate technical variability.
• Biological variability is the natural variation due 
to physiologic differences among subjects or over 
time in the same subject. Biological variance is usu-
ally more pronounced than technical variance and 
must be addressed with greater concern. Biological 
variability can be observed at different levels accord-
ing to the sample type (e.g. cell line, mouse strain 
or human tissue). For instance, while studying the 
BBB from human samples, biological heterogene-
ity might be introduced by several variants, such as 
genetic background, lifestyle, hormonal level, medi-
cal history, sex or age. Differently, when studying the 
BBB from animal models (e.g. mouse), the variants 
that might introduce biological variability are mostly 
age, sex and strain. This reduced number of variants 
is expected to introduce less biological variability in 
samples from animal models when compared to sam-
ples from humans. Although the variability intro-
duced from such variants can be minimized by using, 
inter alia, sex and age matched samples, uncontrolla-
ble biological heterogeneity should be accounted for 
by using biological replicates. For example, human 
BBB samples cannot always be collected in the same 
stage of the male or female hormonal cycles. Since 
it is known that hormones like steroids and estra-
diol regulate BBB permeability and tight junction 
protein expression, respectively, it is important that 
such biological variability is taken into considera-
tion by using biological replicates [173]. Against this 
backdrop, the ideal number of biological replicates 
must be increased when studying very heterogeneous 
samples, species or strains. Currently, most RNA-
Seq experiments include at least three biological 
replicates. A recent study using human whole-blood 
RNA-Seq data shows that the power to detect differ-
entially expressed genes (twofold or higher change) 
is 87% and 98% using three or five biological repli-
cates, respectively. Using three or five replicates, the 
ability to detect smaller changes in expression (1.25-
fold) is 17% and 25%, respectively [174]. Therefore, 
a sequencing depth of 10 million reads and a mini-
mum of 3 to 5 replicates are recommended to reliably 
detect major changes in gene expression. Since add-
ing more replicates is more beneficial than increasing 
sequencing depth, the use of 12 replicates is recom-
mended to detect minor changes in gene expression 
(e.g. 1.25-fold) [170, 175, 176].
Since ribosomal RNA makes up most of the cellular 
RNA, rRNA depletion or mRNA enrichment should be 
performed prior to library preparation. Ribosomal RNA 
depletion or mRNA enrichment methods must be care-
fully chosen depending on the RNAs of interest and the 
integrity of the RNAs. For instance, ribosomal RNA 
depletion can be preferable for degraded material if poly-
A bias is observed.
It is important to understand and choose carefully 
between stranded and unstranded library preparation 
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protocols. Stranded RNA-Seq library preparation is 
characterized by the use of deoxyuridine triphosphate 
(dUTP) instead of deoxythymidine triphosphate (dTTP) 
during the second strand synthesis. Thanks to this altera-
tion, the second strand can be degraded using uracil-N-
glycosylase prior to the PCR amplification and only the 
first strand of cDNA will be amplified and sequenced 
(Fig. 8). A stranded RNA-Seq library retains the informa-
tion of the template DNA strand from which an RNA was 
synthesized. Stranded RNA-Seq performs better in han-
dling read ambiguity in overlapping genes transcribed 
from opposite strands and identifying antisense tran-
scripts. Therefore, strand-specific RNA-Seq is preferred 
to unstranded protocols. However, when well-annotated 
genomes are available (e.g. human or mouse) or when 
analyzing samples with low RNA input, unstranded RNA 
sequencing can be considered nonetheless [177]).
Although not the main focus of this manuscript, since 
they have important applications in the field of brain bar-
riers, we also want to briefly highlight 3′ RNA sequencing 
and small RNA sequencing protocols.
3′ end RNA sequencing is an alternative to RNA-Seq. 
Library preparation techniques are almost identical but 
unlike RNA-Seq, 3′ end RNA sequencing includes an 
enrichment step that, following fragmentation, excludes 
all but the outermost 3′ fragments adjacent to the poly-A 
tail. Due to the information lost during the enrichment 
for terminal fragments, 3′ end RNA-seq is not suited for 
studying open reading frames and, consequently, alter-
natively spliced transcript isoforms. Since 3′ end RNA-
Seq generates exactly one read for each transcript and 
allows the incorporation of unique molecular identifiers 
(UMI) as applied in the Massive Analysis of cDNA Ends 
(MACE) method [178]. The technique also quantifies 
alternative poly-adenylation events which are important 
for mRNA properties such as stability [179]. Notably, 3′ 
end RNA sequencing generates reliable transcriptome 
profiles also from poor-quality samples and is currently 
the main method used in single cell RNA-Seq [180]. 
Thus, this technique can be recommended for quantifica-
tion of gene expression and consequently for determin-
ing the downstream molecular and cellular mechanisms 
essential for brain barriers differentiation and function 
[181].
Several studies have shown the important role of small 
RNA in the molecular mechanisms that control the 
function of the BBB [182]. For example, the microRNA 
miR-27a-3p was identified in intracerebral hemorrhage 
patients to regulate BBB function and edema formation 
via up-regulation of AQP11 [183]. Therefore, small RNA 
sequencing is an important tool to better understand the 
role of small RNAs in the BBB. However, sequencing of 
smaller RNA molecules (e.g. microRNA, piwi-interacting 
RNA, etc.) cannot be performed using regular RNA-Seq 
library preparation techniques because of their rela-
tively small size. Small RNA-Seq library preparation is 
usually performed by ligation of adapters to the RNA 
molecules followed by reverse transcription. The most 
recent kits for library preparation avoid generation of 
adapter-adapter by-products and allow the use of minute 
amounts of starting material.
Guidelines
• Correct RNA quantification and quality control are 
essential to ensure the quality of the sequencing 
results and their reproducibility.
• Strandedness and sequencing strategy have a big 
impact on the analysis and the results. For that rea-
son, they must be carefully chosen.
• Biological replicates are essential and minimum sam-
ple size is affected by extrinsic and intrinsic factors.
• The selection of the correct library preparation tech-
nique is crucial for accurate analysis and should 
be carefully chosen according to the topic under 
research.
Sequencing platforms
After completion of the first human genome sequence, 
the demand for cheaper and faster sequencing methods 
accelerated the development of NGS. Nowadays, NGS 
platforms enable low-cost and high-throughput analy-
ses by sequencing billions of reads in parallel. Two of 
the currently most used short read sequencing methods 
in research labs are Ion Torrent (LifeTechnologies) and 
Illumina sequencing [184]. Although both technolo-
gies rely on sequencing-by-synthesis, Illumina platforms 
detect the fluorescence generated by the incorporation of 
fluorescently labeled nucleotides during DNA synthesis, 
while Ion Torrent platforms detect pH changes induced 
by the release of a hydrogen ion during the incorpora-
tion of a nucleotide into a growing strand of DNA [185, 
186]. The advantages of Ion Torrent platforms are the less 
expensive equipment and the relatively short run time (as 
low as 2 h per run), while its disadvantages are increased 
error rates while sequencing homopolymers, lower 
throughput (up to 80 million reads) and a higher cost per 
base. In contrast, Illumina platforms require expensive 
equipment and a running time up to 3.5 days. The advan-
tages of Illumina platforms are the high-throughput 
capabilities (up to 20 billion reads per run) and the rela-
tively low cost per sequenced base [184]. While Ion Tor-
rent platforms can just perform single-end sequencing 
with read sizes around 200 and 400 base pairs, Illumina 
sequencing platforms have options to perform single-end 
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Fig. 8 Library preparation protocols. Commonly used library preparation protocols for RNA sequencing. For RNA‑Seq, a first step of ribosomal 
RNA (rRNA) depletion from the total RNA is performed; random primers are used for reverse transcription; dUTPs are used for the second strand 
synthesis; Y‑shaped adaptors are then ligated, and then the second strand containing dUTPs is depleted, allowing to retrieve stranded information. 
3′ RNA‑Seq makes use of oligo dT primers for the reverse transcription, which selects mRNA. Using template switching, the second adapter is 
incorporated in the cDNA molecules. Small RNA‑Seq uses adaptors that ligate to the small RNAs and allow the reverse transcription
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or paired-end sequencing and to sequence reads between 
50 and 600 base pairs. Since Illumina and Ion Tor-
rent have similar capabilities to detect differential gene 
expression between samples [187], the choice of the best 
suited platform should be based on the sequencing strat-
egy, cost and time. Additionally, several other technolo-
gies can be used according to the research question at 
hand. For instance, single-molecule real-time sequencing 
technology allows the sequencing of reads with lengths 
up to 100,000 bases and therefore offers a valuable tool 
to study alternative splicing events [188]. The high cost 
of this technology and the high cost to perform expres-
sion profiling studies are its major limitations. Nanopore 
sequencing technology offers an alternative to sequence 
long reads. This technology uses a small and portable 
sequencer and can sequence reads with length up to 
more than 2 million bases [189]. Although the sequenc-
ing throughput is very low, the cost of the sequencing 
devices and reagents is also relatively low.
Guidelines
• Full transcript RNA sequencing can be performed 
using nanopore or single-molecule real-time 
sequencing and might reveal the impact of alterna-
tive splicing variants in the BBB or BCSFB function.
• Gene expression profiling studies from BBB or 
BCSFB samples can be performed using both Illu-
mina and Ion Torrent platforms.
• Sequencing technology and platform should be cho-
sen according to four main criteria:
– Sequencing strategy (single-end or paired-end).
– Read length (e.g. 50, 75, 150, 300 base pairs).
– Desired thought-put.
– Run time.
 .
Data Analysis: Where to focus
Data analysis for RNA-Seq is a multi-step process that 
can be achieved with a plethora of technologies and strat-
egies. A proper analysis should take into consideration all 
the steps mentioned throughout this manuscript as they 
can influence the results and their interpretation. There 
is no optimal “one size fits all” pipeline to be used for all 
different transcriptomic projects in the field of brain bar-
riers, although the overarching steps will mostly be the 
same (Fig.  9). Analysis are often divided into Upstream 
Fig. 9 Overview of the main steps for RNA‑Seq data analysis. 
Raw data goes through quality control steps and, if necessary, 
pre‑processing steps are implemented. Next step is the alignment, 
most commonly in brain barriers studies being through mapping 
to reference. One more round of quality control is recommended 
based on the metrics of the alignment. After sorting, the files can 
be indexed and visualized in a genome browser. Counting can be 
attributed at different levels (gene, exon or transcript) and there are 
multiple algorithms for normalization, both in cases of inter‑sample 
and intra‑sample normalization. Finally, after the differential 
expression analysis, further information can be obtained with steps 
like gene ontology analysis, gene set enrichment analysis or pathway 
analysis
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and Downstream. For the purposes of the current manu-
script, Upstream Analysis consists of the raw FASTQ files 
to the Count Matrix Table and Downstream Analysis 
comprises everything after that.
A major key for a successful data analysis is clear 
communication between the wet lab brain barriers 
researcher, the sequencing facility staff and the bioin-
formaticians allowing for appropriate considerations of 
the respective limitations for optimal achievement of the 
project goals. We believe that there are several good pub-
lications and resources on how to optimize an analytical 
pipeline and benchmarking the different tools [174, 190]. 
As such, we will not discuss it in utmost detail, but we 
will instead focus on some of the steps that we have expe-
rienced to be often overlooked and we will provide some 
recommendations.
Quality control and data pre‑processing: often neglected, 
always important
For the purposes of this paper we will start after the 
demultiplexing process with the FASTQ files. These are 
the raw files that sequencing facilities and companies 
most commonly give to the researchers.
Along with the FASTQ files, researchers usually also 
get a text file with hashes (string of unique characters, in 
this case) for each of the FASTQs. These can be created 
with different algorithms (i.e. md5sum, checksum) and 
are used to ensure that the files were not corrupted dur-
ing transfer. As such, these hashes should always be used 
to check the integrity of the FASTQ files.
Some companies also do some pre-processing steps, for 
instance trimming reads with low quality (in Phred64 or 
Phred33 of the Phred log scale, depending on the version 
and type of the sequencing platform). It is important to 
check if these steps were implemented, and if the answer 
is no, which steps should be. Removing low quality reads, 
for instance, can improve the efficiency of the analysis 
while also removing possible errors.
The most commonly used software for the effect of pre-
alignment quality control (QC) is FastQC [191]. It is easy 
to use (by command line or graphical interface) and cre-
ates intuitive reports (in PDF and HTML format). These 
reports contain information about quality score encod-
ing, the number of reads per sample, reads size, presence 
of contaminants, adapter sequence as well as low quality 
reads and the quality of the reads per position. A drop in 
quality is common both at the beginning and mostly at 
the end of the read and in paired reads; Read 2 (paired 
reads consist of Read1 and Read2) will generally have 
lower quality.
Based on this information it should be decided if the 
raw data is ready for alignment, if it requires pre-pro-
cessing, such as removal of repetitive sequences, or if the 
sequencing or pre-sequencing steps need to be optimized 
and/or repeated.
After mapping the raw data (see next section), a 
genome browser, such as Integrated Genomics Viewer 
(IGV) [192], can be used to visualize the aligned reads. 
Tools like IGV [193] allow for a graphical visualization of 
the BAM files. Importantly, the same version of the refer-
ence genome as the one used to map the raw data must 
be selected. Although not its primary purpose, tools like 
this provide an optic way of visualizing issues such as a 
poly-A bias. A poly-A bias (also known as 3′ Bias) is most 
common in cases of RNA degradation, which is expected 
with the use of human post-mortem samples from the 
CNS, as previously mentioned.
Mapping will also generate metrics regarding over-
all alignment rates, reads aligned to genes, reads 
aligned uniquely versus reads aligned multiple times 
and unmapped reads. A close look at these metrics can 
uncover problems such as sample contamination or DNA 
still present in the sample.
Finally, for post-differential expression analysis, one can 
perform a batch effect test and, if necessary, a batch effect 
correction based either on known variables (samples 
sequenced or prepared on different days, for instance) or 
blindly. Plot visualization is also very informative regard-
ing sample variability, by means of PCA or heatmaps 
colored by group and identified by sample, as an example.
Guidelines
• Quality control must be performed at every step in 
the analysis process.
• There are no hard rules on quality control metrics, 
though all applied quality measures must be men-
tioned in the publication of the data.
• Mapping metrics can inform about problems not 
detected at the raw data level and therefore should be 
taken into account when analyzing the data.
• Data visualization (either post-mapping or post-
differential expression) can be informative regarding 
read distribution and sample variability, respectively.
Overall steps: how to get the desired information 
from your transcriptomics study
While analytical design can be modified to serve the pur-
poses of the analysis, most RNA-Seq experiments with 
the objective of identifying differentially expressed genes 
will follow the same general workflow.
From the raw files, the data is aligned, either by means 
of mapping to an available and curated reference genome 
or by means of performing a de novo transcriptome 
assembly. In the field of brain barriers, the vast majority 
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of experiments are done using vertebrate, well estab-
lished animal models, human tissue or in vitro models of 
the BBB and BCSFB, including cell line models. As such, 
usually, the alignment is done by means of mapping to 
a reference genome of the species of interest. There are 
multiple sources for reference genomes (NCBI—https 
://www.ncbi.nlm.nih.gov/refse q/ and Ensembl—https ://
www.ensem bl.org/index .html—being the most used for 
the referenced species) as well as multiple versions and 
builds. When writing a manuscript, it is imperative to 
reference the source, version and build used for the ref-
erence genome and annotation or precise replication will 
not be possible.
The next major step is quantification, where the 
mapped reads are counted by coordinates and then 
grouped. This grouping can be done at either gene level, 
exon level or transcript level, depending on the objective 
of the study (i.e. is alternative splicing of interest?). This 
choice should be mentioned in publications in order to 
allow the possibility of replication.
After quantification, the count matrix contains the raw 
counts, which need to be normalized. Several normaliza-
tion algorithms are commonly used with different pur-
poses and efficiencies. FPKM (Fragments Per Kilobase of 
transcript per Million mapped reads) and RPKM (Reads 
Per Kilobase of transcript per Million mapped reads) are 
commonly used for intra-sample comparison by normal-
izing for both gene length and library depth. However, 
they have been shown to be inconsistent when compared 
to other methods such as TPM (Transcripts per Million), 
and as such, if intra-sample comparison is the objective, 
the latter has proven more robust [194]. On the other 
side, if inter-sample comparisons are the objective, the 
two most commonly used methods are TMM (Trimmed 
Mean of M-values) from edgeR [195] and RLE (Rela-
tive Log Expression) from DESeq2 [196]. Both of them 
forego the gene length normalization aspect as it is irrel-
evant (inter-sample comparison compares the same gene 
across samples, so they will have the same gene length). 
TMM and RLE have been shown to be consistent and to 
have good performance [197, 198]. However, there are 
differences between them, even if the overall concepts 
are similar. Recommendations for use are based on sam-
ple size, with cases of more than 12 biological replicates, 
DESeq  2 is recommended, while for 12 or fewer repli-
cates, both can be used [176].
With the normalized values calculated, the following 
steps are the differential expression analysis and the gene 
ontology (GO) and pathway analysis. We will discuss cut 
off values and their importance in the next section and 
briefly mention GO and pathways.
Guidelines
• Always reference the source, version and build of the 
reference genome and annotation.
• Indicate the counted feature (Exon, gene or tran-
script).
• Normalization of the counts is mandatory. The 
selected normalization algorithm needs to take into 
account the different strengths and utilities.
Differential expression analysis: cut‑offs, candidate 
selection and cell/tissue purity assessment
After the differential expression analysis to select differ-
entially expressed genes (DEG) a common approach is 
to apply cut-offs to the statistical values obtained, usu-
ally a measure of probability of a false positive, one of 
relative expression and one of absolute expression. One 
of the statistical values obtained is a p-value. These val-
ues should not be used for DEG selection. P-values are 
obtained for comparison between groups on a per gene 
basis without taking into account the number of genes. 
However, when undergoing parallel multiple compari-
sons (as is the case with tens of thousands of genes) 
the likelihood of obtaining false positives will increase. 
To appreciate this, it is necessary to understand what 
p-values actually represent. A p-value is merely a statis-
tical probability that the result/observation for that gene 
would be at least as extreme (the observed difference 
would at least be the same) if the null hypothesis was 
true (that there is actually no difference between the two 
conditions for that gene). As such, if we have a p-value of 
0.01 but 20,000 genes tested, it would be expected that 
200 of those genes were false positives.
In order to solve this issue, a multiple testing correc-
tion is applied. There are a variety of algorithms, some 
of them very strict. Bon Ferroni is probably the simplest 
and the strictest one. It consists of dividing the α (cho-
sen significance level, usually 0.05 or 0.01) by the number 
of tests (genes) to get a new α. However, while increasing 
confidence on the genes that do pass the new significance 
threshold (increased True Positive Rate) it is probable 
that there is a concomitant increase of the false negative 
ratio. A more appropriate correction is the Benjamini–
Hochberg correction [199], which produces an adjusted 
p-value that can then be judged on the same initial α, 
most predominantly known as false discovery rate (FDR).
Another option is to ignore the p-value (adjusted 
or not) and focus solely on the fold change. Massively 
simplifying it, the fold change indicates the order of 
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magnitude of the difference for that gene between con-
ditions. This allows for the discard of genes where there 
are small differences that may be difficult or impossible 
to validate by qPCR and especially at the protein level, 
due to problems pertaining to low depth and the RNA–
Protein abundance discrepancy [200]. Also, it should be 
mentioned that thresholds for log2FC (the base 2 loga-
rithmic transformation of Fold Change that allows one to 
discern the direction—up and down—of regulation) are 
not as well defined and accepted.
A commonly used solution is to apply cut-offs for both 
the FDR and the log2FC, potentially also combined with 
an extra cut-off for overall expression.
If the goal of the experiment is mechanism or process 
discovery, pathway and enrichment analysis can provide 
guides of where to proceed in the functional validation. 
However, there are a few issues that we found problem-
atic and should be considered.
Firstly, these analyses are heavily dependent on the 
quality of the respective databases used. For instance, the 
more a respective field is studied (e.g. cancer) the more 
information about that field is included in the database. 
The corollary is that the less that is known in a specific 
research field or about a molecule or mechanism, the less 
information will be available [201].
Secondly, there is a trend to use commercial tools for 
pathway and gene ontology analysis. While the tools 
appear to be solid, their restricted availability complicates 
reproducibility of the results. Thus, we recommend the 
use of open source tools for the same purpose instead.
Finally, while it is possible to have an estimation of cell 
and tissue purity based on the results from transcriptom-
ics studies, the methodologies to do just that should not 
be relied upon. The advent of extensive datasets, such as 
the one from Vanlandewijck and colleagues [13] can pro-
vide useful and necessary data points but will need to be 
supplemented with deep bulk RNA-Seq datasets. This is 
especially true for the expression of genes such as clau-
din-3 and claudin-12, which were previously thought to 
be signature claudins of the BBB, which has recently been 
disproven or put in another perspective [79, 202].
Guidelines
• In RNA-Seq studies p-values require multiple test 
correction. However, overly harsh multiple test cor-
rection can increase the False Negative Ratio of dif-
ferentially expressed genes.
• The use of individual cut-offs and or mixes have their 
strengths and should be used in accordance to the 
objective.
• The intrinsic limitation of pathway and enrichment 
analysis should be taken into account.
Validation of transcriptomics results: Challenges 
and recommendations
It is often requested by journals or reviewers to validate 
RNA-Seq results in two ways. The first one is by qPCR. 
This RNA level validation can be performed either on the 
same samples as the RNA-Seq or on different ones. It is 
an open debate if qPCR validation is actually necessary. It 
is our opinion that, while not absolutely necessary, qPCR 
validation can provide valuable information. When done 
on the same samples, qPCR can validate the sequencing 
process, while validation of the results using a different 
set of biological replicates can help confirm the results 
[203].
The other validation approach is at the protein level. 
This can be achieved by different methodologies includ-
ing Western Blots (WB), immunohistochemistry (IHC) 
and immunofluorescence (IF) staining. WBs tend to be 
more informative when it comes to quantification values, 
IHC and IF staining on the other hand allow for cellular 
and subcellular location of the protein being investigated. 
Protein level validation should be performed prior to 
functional studies based on the chosen candidates from 
the RNA-Seq results. Common issues are the absence of 
correlation between protein and RNA levels or of the dif-
ferential expression detected amongst groups due to the 
RNA–protein discrepancy [200].
Data storage and availability
Upon publication of the manuscript, all relevant data 
should be made accessible. This necessarily includes the 
raw data but can also include processed data and any rel-
evant metadata. There are a number of specialized data 
repositories, including GEO (https ://www.ncbi.nlm.nih.
gov/geo/), SRA (https ://www.ncbi.nlm.nih.gov/sra) and 
the European Nucleotide Archive (ENA—https ://www.
ebi.ac.uk/ena). As most of the data repositories allow for 
the data to remain private until publication, it is recom-
mended that the process of uploading the data is done in 
advance. This also allows to provide the reviewers with 
access tokens. Outside of public data repositories, local 
copies of the data should also be stored and maintained.
As a complement, some groups have in addition cre-
ated web-interfaces allowing other researchers to explore 
their results. This includes BBBomics (http://bioin forma 
ticst ools.mayo.edu/bbbom ics/) [97], the Vascular Sin-
gle Cells Database (http://betsh oltzl ab.org/Vascu larSi 
ngleC ells/datab ase.html) [13, 76], Brain RNA-Seq (https 
://www.brain rnase q.org/) [204, 205], Single Cell Analysis 
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of Mouse Cortex (http://linna rsson lab.org/corte x/) [206] 
and the Allen Brain Map (https ://porta l.brain -map.org/). 
These web interfaces are usually representative of stud-
ies that focus on the assessment of molecular expression 
in specific tissues or cell types and can be valuable tools 
when designing a new experiment or doing quality con-
trol and purity assessment of bulk RNA-Seq data.
Publishing recommendations for RNA‑Seq studies 
in the field of brain barriers
• Include a description of the selected region/tissue/
cell type (i.e. capillary endothelial cells from the pre-
frontal cortex) as well as discarded regions/tissues/
cell types (through different purification steps.
• Provide a detailed barriers isolation protocol using 
a schematic overview that addresses the following 
points:
– Relevant details on the tissue source: age, sex and 
for animal strains and for humans detailed informa-
tion on the individuals as applicable.
– Rational for specific brain barriers isolation meth-
odologies used.
– In depth information on workflow of isolation pro-
tocol including precise information on digestion 
and size-dependent selection steps applied.
– For bead selection, mention advantages and disad-
vantages of the used antibodies.
– Obtained yield of biological material.
– Test for purity and its result including the rationale 
for testing for specific contaminants and methodol-
ogy applied.
 .
• Description of the RNA extraction protocol can be 
less extensive than that for tissue isolation. How-
ever, it should clearly indicate RNA integrity values 
(or range) as well as quantification.
• Add sequencing specific information, including:
– Library enrichment—RNAs of interest.
– Platform.
– Pairedness.
– Strandedness.
– Depth (range).
– Replicates per group.
 .
• Provide data analysis details:
– When possible a standardization of a simplified 
script as supplementary material in all publications.
– Simplified schematic analytical pipeline with tools 
and processes.
– Relevant Quality Control information.
– Metrics used throughout the paper, such as nor-
malization values, cut-offs (Adjusted P-value and 
Fold Change for instance). Keep consistent, explain 
if not.
– Further criteria for selection should be made clear 
(possibly in the discussion section, rather than 
methodology).
 .
• While referring to protocols in the methods sec-
tion, point to original paper and make the differ-
ences to it clear. Alternatively, include a detailed 
protocol in the supplementary material.
• At the time of publication make both the raw data, 
the analyzed data and any relevant metadata pub-
licly available.
Emerging transcriptomics applications for the field of brain 
barriers
As mentioned above, the present manuscript has focused 
on the application of bulk RNA-Seq in the field of brain 
barriers research. New applications in the field of tran-
scriptomics are however emerging and may thus be of 
equal significance in the near future.
scRNA-Seq is perhaps the most established and known 
in brain barriers research. Several studies have used this 
methodology to great effect allowing to discover a previ-
ously unknown diversity of cells in the brain and the brain 
vasculature, respectively [13, 206]. Single nucleus RNA-
Seq (snRNA-Seq) is an alternative method to scRNA-Seq. 
While it presents a limitation in that only nuclear RNA will 
be captured and sequenced, it has the advantage of not 
requiring live dissociated cells. As such, it was used in con-
jugation with scRNA-Seq to compare adult and embryonic 
transcriptomic profiles of the ChP in the cases where dis-
sociation failed to produce viable cells [42].
Spatial RNA-Seq is a recent technique that allows to 
sequence tissue sections in a way that the transcriptomic 
profiles can be attributed back to different locations in the 
section, with each location corresponding to a uniquely 
barcoded spot. Briefly, a tissue section is placed on a spe-
cial microscopic slide (coated with spatial barcode oligos) 
that allows to maintain positional information throughout 
the sequencing process. As such, in conjugation with a 
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previously acquired image of the section taken beforehand, 
it is possible to attribute specific transcriptomic profiles 
to regions in the tissue section. At present the resolution 
of spatial RNA-Seq allows to distinguish about 5000 spots 
per slide with each spot having a 55  µm diameter and 
a 100  µm center to center distance between spots. Thus, 
this technology is not well suited for precise assignment 
of transcriptomic information to the fine structures of the 
microvasculature (such as BBB microvessels), but rather to 
focal areas in the brain and spinal cord allowing to deter-
mine regional differences in the transcriptome in the brain 
and spinal cords in health and disease [207, 208]. As the 
resolution and the technology improves it has the poten-
tial to become a valuable tool for brain barriers research.
As a final note of this section, it is important to point 
out that none of the mentioned technologies will 
replace bulk RNA-Seq. Rather, they provide alternative 
or supplementary technology to bulk RNA-Seq and are 
accompanied by different strengths and weaknesses. For 
instance, scRNA-Seq usually requires live, viable, dissoci-
ated cells and transcripts of low and medium expression 
will be underrepresented. The choice of which technol-
ogy is appropriate should be made based on what the 
objectives of the study in question are as well as extrinsic 
factors, such as cost. This decision should be made early 
on the process and the input of a sequencing facility tech-
nician and of a bioinformatician is valuable to the wet-lab 
researcher.
Concluding remarks
This manuscript intends to provide a valuable and 
exhausting source of information for brain barriers 
researchers and bioinformaticians when planning RNA-
Seq analysis in the context of brain barriers research 
based on the experiences made in the BtRAIN network. 
Our intention is that this manuscript incites closer inter-
action between classical brain barriers researchers and 
bioinformaticians in planning and performing RNA-Seq 
analysis. We are convinced that considering the issues 
raised here will allow for future publication of studies 
providing more specific and accurate information which 
is prerequisite for data comparison and replication.
Glossary
• Alignment and Mapping: Alignment is the process 
of attributing reads to the corresponding place in 
the genome/transcriptome. Mapping usually refers 
exclusively to doing this process by aligning the reads 
to a reference genome while alignment can also refer 
to a de novo assembly.
• Batch effect: Type of variability not related to the 
biological question that can obfuscate the results. It 
tends to have a technical source and it is usually hard 
to pinpoint. Can be due to different labs, different 
time days for RNA extraction as well as many other 
factors.
• BAM file: Binary form of a SAM file (Sequence 
Alignment/Map), which is the file resulting from the 
alignment. These files can be sorted by gene name of 
by genomic coordinates.
• Checksum (i.e. md5sum): algorithm that creates an 
“hash” (a string of characters) corresponding to a file. 
Since small changes to the file completely alter this 
string it can be used to detect corruption of the file 
during transfer.
• Demultiplexing: in silico process of assigning the 
reads back to the corresponding sample. During 
sequencing samples are often multiplexed (pooled 
and sequenced together) making demultiplexing an 
essential step.
• Downstream Analysis: Usually refers to the more 
flexible statistical steps that start with the counts 
matrix. It includes, amongst others, normalization, 
differential expression analysis, batch effect correc-
tion, multiple testing correction and annotation.
• FASTQ: file type that stores the biological sequence 
alongside the corresponding PHRED scores. It is usu-
ally the file with which the analysis starts.
• Fluorescence-activated cell sorting (FACS): tech-
nique that uses flow cytometry to sort a heterogene-
ous mixture of cells into two or more groups based 
upon light scattering and fluorescent characteristics.
• Genome Browser: Tool that allows for direct visu-
alization of the reads aligned to a reference genome 
using the coordinate sorted BAM files.
• Laser capture microdissection (LCM): technique that 
allows the dissection and isolation of cells or tissue. It 
uses direct microscopic visualization and a laser. Dis-
sected material can be captured by absorption, ejec-
tion, gravity or aspiration.
• Paired or single-end reads: single-end reads are only 
sequenced from one end of the DNA fragment while 
paired-end reads are sequenced from both ends. This 
will have an impact on certain features, for instance, 
paired-end reads are better suited for the discovery of 
novel alternative splicing sites.
• PHRED score: Logarithmic quality score for base-
calling errors. The higher the score, the less the prob-
ability of an error for each base. A PHRED of 3, for 
instance, corresponds to a 50% probability of a cor-
rect call while a PHRED score of 30 corresponds to a 
99.9% probability of a correct call.
• Principal component analysis (PCA): statistical 
method that uses the provided data (for RNA-Seq it 
usually is the gene expression values) to define unre-
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lated variables. Usually presented as either 2 or 3 
dimensional, it can be used in an exploratory fashion 
to access the sources of variability in the data.
• Quantification: Also sometimes referred to as count-
ing. In this step reads are attributed to features. These 
features can be genes, transcripts or exons.
• Transcriptome: complete set of transcripts (RNA 
molecules) in a cell, and their quantity, for a specific 
developmental stage or physiological condition.
• Transcriptomics: the study of transcriptomes and 
their functions.
• Raw files: files that have not been processed, usually 
referring to the fastq files.
• RNA-sequencing (RNA-Seq): high-throughput 
method for both mapping and quantifying transcrip-
tomes.
• Upstream Analysis: Usually refers to the analysis 
up until a count file is generated. This includes, but 
is not restricted to, trimming, alignment, sorting, 
counting and the initial quality control steps.
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